Delivery of platinum (II) drugs with bulky ligands in trans-geometry for overcoming cisplatin drug resistance.

Drug resistance induced by increasing intracellular levels of detoxifying agents for conventional platinum(II) drugs such as metallothioneins (MTs) and glutathione (GSH) are the major obstacles for widely used platinum-based chemotherapeutic cancer treatment. Here, we developed trans-geometry platinum (II) drugs with sterically hindered bulky ligands PyPt which is able to hind the GSH attack of platinum drug to overcome cisplatin resistance. Moreover, the PyPt can self-assemble with biodegradable copolymer mPEG-PGA into uniform nanoparticles with PyPt drugs in the polymeric core and PEG as the shell, further protecting PyPt from GSH detoxification to further slow the reaction rate with GSH in vivo. This strategy was developed to bring benefit of not only increasing the solubility of sterically hindered platinum drugs but also combating cisplatin resistance. The M(PyPt) exhibited environment controlled releasing of Pt in tumor micro-environment which prohibited the division of cancer cells. Furthermore, due to the increasing solubility of nanoparticle encapsulated PyPt, the cellular uptake and cytotoxicity of M(PyPt) against both cancer resistance cells was enhanced compared to the cisplatin and PyPt through evaluating with flow cytometry and MTT, respectively. Thus, it was concluded that the M(PyPt) was capable to successfully overcome the cisplatin resistance in the drug-resistant cell line, indicating its potential application in the treatment of clinical cancers with strong cisplatin resistance. Hence the M(PyPt) strategy may represent a promising novel drug delivery system for the local treatment of drug resistance cancer.

[1]  S. Choo,et al.  Phase I/II Study of NC-6004, A Novel Micellar Formulation of Cisplatin, In Combination with Gemcitabine in Patients with Pancreatic Cancer in Asia - Results of Phase I , 2012 .

[2]  X. Jing,et al.  Nanoparticle delivery of photosensitive Pt(IV) drugs for circumventing cisplatin cellular pathway and on-demand drug release. , 2014, Colloids and surfaces. B, Biointerfaces.

[3]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Haihua Xiao,et al.  Advances in drug delivery system for platinum agents based combination therapy , 2015, Cancer biology & medicine.

[5]  Y. Matsumoto,et al.  Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[6]  M. Tsai,et al.  Using MTT viability assay to test the cytotoxicity of antibiotics and steroid to cultured porcine corneal endothelial cells. , 1996, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[7]  Honghao Zhou,et al.  Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non‐small cell lung carcinoma patients , 2012, Clinical and experimental pharmacology & physiology.

[8]  L. Belov,et al.  The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. , 1992, Leukemia research.

[9]  X. Jing,et al.  A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting , 2015, Anti-cancer drugs.

[10]  X. Jing,et al.  Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Xuemin Wang,et al.  NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells , 2016, Oncotarget.

[12]  X. Jing,et al.  Micellar nanoparticle formation via electrostatic interactions for delivering multinuclear platinum(II) drugs. , 2013, Chemical communications.

[13]  X. Jing,et al.  A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy. , 2012, Chemical communications.

[14]  X. Jing,et al.  Polymer nanoparticle delivery of dichloroacetate and DACH-Pt to enhance antitumor efficacy and lower systemic toxicity. , 2016, Biomaterials science.

[15]  Jie Tian,et al.  Metal–Organic‐Framework‐Derived Mesoporous Carbon Nanospheres Containing Porphyrin‐Like Metal Centers for Conformal Phototherapy , 2016, Advanced materials.

[16]  Yingjie Yu,et al.  Quantitative real-time detection of carcinoembryonic antigen (CEA) from pancreatic cyst fluid using 3-D surface molecular imprinting. , 2016, The Analyst.

[17]  X. Jing,et al.  Turning Ineffective Transplatin into a Highly Potent Anticancer Drug via a Prodrug Strategy for Drug Delivery and Inhibiting Cisplatin Drug Resistance. , 2016, Bioconjugate chemistry.

[18]  Qi Zhang,et al.  Design of a molecular imprinting biosensor with multi-scale roughness for detection across a broad spectrum of biomolecules. , 2016, The Analyst.

[19]  Yangzhong Liu,et al.  Glutathione selectively modulates the binding of platinum drugs to human copper chaperone Cox17. , 2015, The Biochemical journal.

[20]  S. Howell,et al.  Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells , 2004, Cancer Chemotherapy and Pharmacology.

[21]  Qi Zhang,et al.  Increasing the Detection Sensitivity for DNA-Morpholino Hybridization in Sub-Nanomolar Regime by Enhancing the Surface Ion Conductance of PEDOT:PSS Membrane in a Microchannel , 2016 .

[22]  X. Jing,et al.  Biodegradable polymer - cisplatin(IV) conjugate as a pro-drug of cisplatin(II). , 2011, Biomaterials.

[23]  L. Kèlland,et al.  Broadening the clinical use of platinum drug–based chemotherapy with new analogues , 2007, Expert opinion on investigational drugs.

[24]  Alexander Johnson-Buck,et al.  A two-layer assay for single-nucleotide variants utilizing strand displacement and selective digestion. , 2016, Biosensors & bioelectronics.

[25]  Bundling potent natural toxin cantharidin within platinum (IV) prodrugs for liposome drug delivery and effective malignant neuroblastoma treatment. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[26]  Stephanie E. A. Gratton,et al.  The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.

[27]  V. Horváth,et al.  Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin , 2007, Investigational New Drugs.

[28]  C. Ober,et al.  Manipulation of cell adhesion and dynamics using RGD functionalized polymers. , 2017, Journal of materials chemistry. B.

[29]  Linlin Li,et al.  Advances in biodegradable nanomaterials for photothermal therapy of cancer , 2016, Cancer biology & medicine.

[30]  O. Lipatov,et al.  Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  K. Kataoka,et al.  Tumor‐targeted chemotherapy with the nanopolymer‐based drug NC‐6004 for oral squamous cell carcinoma , 2013, Cancer science.

[32]  X. Jing,et al.  Nanoparticle delivery of sterically hindered platinum(IV) prodrugs shows 100 times higher potency than that of cisplatin upon light activation. , 2016, Chemical communications.

[33]  P. Sadler,et al.  A potent trans-diimine platinum anticancer complex photoactivated by visible light. , 2010, Angewandte Chemie.

[34]  V. Sriuranpong,et al.  Impact of the Copper Transporter Protein 1 (CTR1) Polymorphism on Adverse Events among Advanced NonSmall Cell Lung Cancer Patients Treated with a Carboplatin/Gemcitabine Regimen. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[35]  N. Nishiyama,et al.  Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats , 2005, British Journal of Cancer.

[36]  M. Hemann,et al.  Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer , 2017, Nature Communications.

[37]  M. Meyerhoff,et al.  An Ionophore-Based Anion-Selective Optode Printed on Cellulose Paper. , 2017, Angewandte Chemie.

[38]  E. Guancial,et al.  Role of copper transporters in platinum resistance. , 2016, World journal of clinical oncology.

[39]  G. Hamilton,et al.  Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer , 2013, Expert opinion on drug metabolism & toxicology.

[40]  Y. Matsumura.  The drug discovery by nanomedicine and its clinical experience. , 2014, Japanese journal of clinical oncology.

[41]  Irfan Rahman,et al.  Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method , 2006, Nature Protocols.

[42]  Matti Kaisti,et al.  Polyaniline-functionalized ion-sensitive floating-gate FETs for the on-chip monitoring of peroxidase-catalyzed redox reactions , 2018 .

[43]  Vera Bandmann,et al.  Uptake of fluorescent nano beads into BY2‐cells involves clathrin‐dependent and clathrin‐independent endocytosis , 2012, FEBS letters.

[44]  B. Deurs,et al.  Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. , 1999, Molecular biology of the cell.

[45]  A. Boddy,et al.  A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours , 2011, British Journal of Cancer.

[46]  Leming Sun,et al.  Polymer materials for prevention of postoperative adhesion. , 2017, Acta biomaterialia.